• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过分子间互补形成功能性转位孔的炭疽毒素变体的抗肿瘤活性。

Anti-tumor activity of anthrax toxin variants that form a functional translocation pore by intermolecular complementation.

作者信息

Liu Shihui, Ma Qian, Fattah Rasem, Bugge Thomas H, Leppla Stephen H

机构信息

Proteases and Tissue Remodeling Section, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892, USA.

Microbial Pathogenesis Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

出版信息

Oncotarget. 2017 May 9;8(39):65123-65131. doi: 10.18632/oncotarget.17729. eCollection 2017 Sep 12.

DOI:10.18632/oncotarget.17729
PMID:29029417
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5630317/
Abstract

Anthrax lethal toxin is a typical A-B type protein toxin secreted by . Lethal factor (LF) is the catalytic A-subunit, a metalloprotease having MEKs as targets. LF relies on the cell-binding B-subunit, protective antigen (PA), to gain entry into the cytosol of target cells. PA binds to cell surface toxin receptors and is activated by furin protease to form an LF-binding-competent oligomer-PA pre-pore, which converts to a functional protein-conductive pore in the acidic endocytic vesicles, allowing translocation of LF into the cytosol. During PA pre-pore-to-pore conversion, the intermolecular salt bridge interactions between Lys397 and Asp426 on adjacent PA protomers play a critical role in positioning neighboring luminal Phe427 residues to form the Phe-clamp, an essential element of the PA functional pore. This essential intermolecular interaction affords the opportunity to create pairs of PA variants that depend on intermolecular complementation to form a functional pore. We have previously generated PA variants with furin-cleavage site replaced by substrate sequences of tumor-associated proteases, such as urokinase or MMPs. Here we show that PA-U2-K397Q, a urokinase-activated PA variant with Lys397 residue replaced by glutamine, and PA-L1-D426K, a MMP-activated PA variant with Asp426 changed to lysine, do not form functional pores both or unless they are used together. Further, the mixture of PA-U2-K397Q and PA-L1-D426K displayed potent anti-tumor activity in the presence of LF. Thus, PA-U2-K397Q and PA-L1-D426K form a novel intermolecular complementation system with toxin activation relying on the presence of two distinct tumor-associated proteases, i.e., urokinase and MMPs.

摘要

炭疽致死毒素是由……分泌的一种典型的A-B型蛋白质毒素。致死因子(LF)是催化性A亚基,是一种以MEKs为靶点的金属蛋白酶。LF依赖细胞结合性B亚基保护性抗原(PA)进入靶细胞的胞质溶胶。PA与细胞表面毒素受体结合,并被弗林蛋白酶激活形成具有LF结合能力的寡聚体——PA前孔,该前孔在酸性内吞小泡中转化为功能性蛋白质传导孔,使LF能够转运到胞质溶胶中。在PA前孔到孔的转化过程中,相邻PA原体上的Lys397和Asp426之间的分子间盐桥相互作用在定位相邻腔面Phe427残基以形成Phe钳(PA功能孔的关键元件)方面起着关键作用。这种关键的分子间相互作用提供了创造依赖分子间互补形成功能性孔的PA变体对的机会。我们之前已经生成了将弗林蛋白酶切割位点替换为肿瘤相关蛋白酶(如尿激酶或基质金属蛋白酶)底物序列的PA变体。在这里我们表明,PA-U2-K397Q(一种将Lys397残基替换为谷氨酰胺的尿激酶激活的PA变体)和PA-L1-D426K(一种将Asp426替换为赖氨酸的基质金属蛋白酶激活的PA变体),单独使用时都不能形成功能性孔,除非它们一起使用。此外,在存在LF的情况下,PA-U2-K397Q和PA-L1-D426K的混合物表现出强大的抗肿瘤活性。因此,PA-U2-K397Q和PA-L1-D426K形成了一种新型的分子间互补系统,毒素激活依赖于两种不同的肿瘤相关蛋白酶(即尿激酶和基质金属蛋白酶)的存在。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9ef/5630317/072ac5f43506/oncotarget-08-65123-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9ef/5630317/3facc05fa56c/oncotarget-08-65123-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9ef/5630317/9bb846ee72e9/oncotarget-08-65123-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9ef/5630317/072ac5f43506/oncotarget-08-65123-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9ef/5630317/3facc05fa56c/oncotarget-08-65123-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9ef/5630317/9bb846ee72e9/oncotarget-08-65123-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9ef/5630317/072ac5f43506/oncotarget-08-65123-g003.jpg

相似文献

1
Anti-tumor activity of anthrax toxin variants that form a functional translocation pore by intermolecular complementation.通过分子间互补形成功能性转位孔的炭疽毒素变体的抗肿瘤活性。
Oncotarget. 2017 May 9;8(39):65123-65131. doi: 10.18632/oncotarget.17729. eCollection 2017 Sep 12.
2
An anthrax toxin variant with an improved activity in tumor targeting.一种在肿瘤靶向方面具有改进活性的炭疽毒素变体。
Sci Rep. 2015 Nov 20;5:16267. doi: 10.1038/srep16267.
3
Tumor Imaging Using Radiolabeled Matrix Metalloproteinase-Activated Anthrax Proteins.基于放射性标记的基质金属蛋白酶激活炭疽蛋白的肿瘤成像。
J Nucl Med. 2019 Oct;60(10):1474-1482. doi: 10.2967/jnumed.119.226423. Epub 2019 Apr 6.
4
Dissecting the urokinase activation pathway using urokinase-activated anthrax toxin.使用尿激酶激活的炭疽毒素剖析尿激酶激活途径。
Methods Mol Biol. 2009;539:175-90. doi: 10.1007/978-1-60327-003-8_10.
5
Asymmetric Cryo-EM Structure of Anthrax Toxin Protective Antigen Pore with Lethal Factor N-Terminal Domain.炭疽毒素保护性抗原孔与致死因子 N 端结构域的非对称低温电镜结构
Toxins (Basel). 2017 Sep 22;9(10):298. doi: 10.3390/toxins9100298.
6
Anthrax protective antigen cleavage and clearance from the blood of mice and rats.炭疽保护性抗原在小鼠和大鼠血液中的裂解与清除
Infect Immun. 2007 Nov;75(11):5175-84. doi: 10.1128/IAI.00719-07. Epub 2007 Aug 27.
7
Anthrax toxin.炭疽毒素。
Annu Rev Cell Dev Biol. 2003;19:45-70. doi: 10.1146/annurev.cellbio.19.111301.140655.
8
Membrane type-1 matrix metalloproteinase (MT1-MMP) protects malignant cells from tumoricidal activity of re-engineered anthrax lethal toxin.膜型-1基质金属蛋白酶(MT1-MMP)可保护恶性细胞免受经重新设计的炭疽致死毒素的杀肿瘤活性影响。
Int J Biochem Cell Biol. 2005 Jan;37(1):142-54. doi: 10.1016/j.biocel.2004.06.005.
9
Pre-labelling versus direct labelling of anthrax proteins for imaging of matrix metalloproteinases activity using DOTA-GA.使用 DOTA-GA 对炭疽蛋白进行预标记与直接标记以进行基质金属蛋白酶活性成像。
Nucl Med Biol. 2019 May-Jun;72-73:49-54. doi: 10.1016/j.nucmedbio.2019.07.007. Epub 2019 Jul 18.
10
Bismaleimide cross-linked anthrax toxin forms functional octamers with high specificity in tumor targeting.双马来酰亚胺交联炭疽毒素在肿瘤靶向中形成具有高特异性的功能性八聚体。
Protein Sci. 2019 Jun;28(6):1059-1070. doi: 10.1002/pro.3613. Epub 2019 Apr 17.

引用本文的文献

1
From pathogenicity to therapy: Investigating the Therapeutic Potential of Bacillus anthracis Anthrax Toxin in Novel Cancer Therapies and Oncological Research.从致病性到治疗:探究炭疽杆菌炭疽毒素在新型癌症治疗和肿瘤学研究中的治疗潜力
Arch Microbiol. 2025 Jul 31;207(9):205. doi: 10.1007/s00203-025-04407-y.
2
ERK and c-Myc signaling in host-derived tumor endothelial cells is essential for solid tumor growth.宿主来源的肿瘤内皮细胞中的 ERK 和 c-Myc 信号对于实体瘤的生长是必需的。
Proc Natl Acad Sci U S A. 2023 Jan 3;120(1):e2211927120. doi: 10.1073/pnas.2211927120. Epub 2022 Dec 27.
3
A potent tumor-selective ERK pathway inactivator with high therapeutic index.

本文引用的文献

1
Solid tumor therapy by selectively targeting stromal endothelial cells.通过选择性靶向基质内皮细胞进行实体瘤治疗。
Proc Natl Acad Sci U S A. 2016 Jul 12;113(28):E4079-87. doi: 10.1073/pnas.1600982113. Epub 2016 Jun 29.
2
An anthrax toxin variant with an improved activity in tumor targeting.一种在肿瘤靶向方面具有改进活性的炭疽毒素变体。
Sci Rep. 2015 Nov 20;5:16267. doi: 10.1038/srep16267.
3
Anthrax Pathogenesis.炭疽病发病机制。
一种具有高治疗指数的强效肿瘤选择性ERK通路抑制剂。
PNAS Nexus. 2022 Jul 1;1(3):pgac104. doi: 10.1093/pnasnexus/pgac104. eCollection 2022 Jul.
4
IgG-Engineered Protective Antigen for Cytosolic Delivery of Proteins into Cancer Cells.用于将蛋白质胞质递送至癌细胞的IgG工程化保护性抗原。
ACS Cent Sci. 2021 Feb 24;7(2):365-378. doi: 10.1021/acscentsci.0c01670. Epub 2021 Feb 4.
5
Harnessing the Membrane Translocation Properties of AB Toxins for Therapeutic Applications.利用 AB 毒素的膜转位特性进行治疗应用。
Toxins (Basel). 2021 Jan 6;13(1):36. doi: 10.3390/toxins13010036.
6
Targeting Cancer Gene Dependencies with Anthrax-Mediated Delivery of Peptide Nucleic Acids.用炭疽介导的肽核酸递送来靶向癌症基因依赖性。
ACS Chem Biol. 2020 Jun 19;15(6):1358-1369. doi: 10.1021/acschembio.9b01027. Epub 2020 May 11.
7
Bismaleimide cross-linked anthrax toxin forms functional octamers with high specificity in tumor targeting.双马来酰亚胺交联炭疽毒素在肿瘤靶向中形成具有高特异性的功能性八聚体。
Protein Sci. 2019 Jun;28(6):1059-1070. doi: 10.1002/pro.3613. Epub 2019 Apr 17.
8
Did evolution create a flexible ligand-binding cavity in the urokinase receptor through deletion of a plesiotypic disulfide bond?通过删除一个古老的二硫键,进化是否在尿激酶受体中创造了一个灵活的配体结合腔?
J Biol Chem. 2019 May 3;294(18):7403-7418. doi: 10.1074/jbc.RA119.007847. Epub 2019 Mar 20.
9
Application of built-in adjuvants for epitope-based vaccines.基于表位的疫苗中内置佐剂的应用。
PeerJ. 2019 Jan 14;6:e6185. doi: 10.7717/peerj.6185. eCollection 2019.
Annu Rev Microbiol. 2015;69:185-208. doi: 10.1146/annurev-micro-091014-104523. Epub 2015 Jul 16.
4
Targeting RAS-ERK signalling in cancer: promises and challenges.靶向癌症中的 RAS-ERK 信号通路:前景与挑战。
Nat Rev Drug Discov. 2014 Dec;13(12):928-42. doi: 10.1038/nrd4281.
5
Anthrax lethal and edema toxins in anthrax pathogenesis.炭疽致病过程中的炭疽致死毒素和水肿毒素。
Trends Microbiol. 2014 Jun;22(6):317-25. doi: 10.1016/j.tim.2014.02.012. Epub 2014 Mar 27.
6
Cytolethal distending toxin B as a cell-killing component of tumor-targeted anthrax toxin fusion proteins.细胞致死膨胀毒素 B 作为肿瘤靶向炭疽毒素融合蛋白的细胞杀伤成分。
Cell Death Dis. 2014 Jan 16;5(1):e1003. doi: 10.1038/cddis.2013.540.
7
Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression.间皮瘤在用抗间皮素免疫毒素和免疫抑制治疗后出现主要肿瘤消退。
Sci Transl Med. 2013 Oct 23;5(208):208ra147. doi: 10.1126/scitranslmed.3006941.
8
Key tissue targets responsible for anthrax-toxin-induced lethality.导致炭疽毒素致死的关键组织靶标。
Nature. 2013 Sep 5;501(7465):63-8. doi: 10.1038/nature12510. Epub 2013 Aug 28.
9
Receptor-directed chimeric toxins created by sortase-mediated protein fusion.基于 sortase 介导的蛋白融合技术构建的受体导向嵌合毒素
Mol Cancer Ther. 2013 Oct;12(10):2273-81. doi: 10.1158/1535-7163.MCT-13-0358. Epub 2013 Aug 14.
10
Engineering anthrax toxin variants that exclusively form octamers and their application to targeting tumors.工程炭疽毒素变体,其仅形成八聚体及其在肿瘤靶向中的应用。
J Biol Chem. 2013 Mar 29;288(13):9058-65. doi: 10.1074/jbc.M113.452110. Epub 2013 Feb 7.